GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.67 USD
+0.54 (1.25%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $43.68 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
GSK 43.67 +0.54(1.25%)
Will GSK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Stock Reports for Apple, Tesla & NextEra Energy
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
3 Top Dividend Stocks to Maximize Your Retirement Income
Other News for GSK
GSK announces Phase III trial of Nucala met primary endpoint
GSK’s Nucala succeeds in late-stage study for lung disorder, COPD
GSK hails positive results of Nucala clinical trials in lung disease
Innoviva's Rollercoaster: Critical Care Bets With Respiratory Backing
Deutsche Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)